利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

116 条记录 (耗时 0.02 秒)

    NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    61.
    发明公开
    NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    NITROSIERTE UND NITROSYLIERTE NICHTSTEROIDALE ANTIPHLOGISTISHE VERBINDUNGIS，ZUSAMMENSTELLUNGEN UND VERWENDUNGSMETHODEN

    公开(公告)号：EP1126838A1

    公开(公告)日：2001-08-29

    申请号：EP99958708.2

    申请日：1999-10-29

    申请人： Nitromed, Inc.

    发明人： BANDARAGE, Upul, K. ,  DONG, Qing ,  FANG, Xinqin ,  GARVEY, David, S. ,  MERCER, Gregory, J. ,  RICHARDSON, Stewart, K. ,  SCHROEDER, Joseph, D. ,  WANG, Tiansheng

    IPC分类号： A61K31/381

    CPC分类号： C07D207/08 ,  A61K45/06 ,  C07C381/00 ,  C07C2601/14 ,  C07D209/28 ,  C07D211/22 ,  C07D211/26 ,  C07D211/54 ,  C07D211/62 ,  C07D239/47 ,  C07D241/06 ,  C07D263/20 ,  C07D295/088 ,  C07D295/185 ,  C07D295/192 ,  C07D317/32 ,  C07F9/4006 ,  C07F9/4075

    摘要： The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

    摘要翻译： 本发明描述了新的亚硝化和/或亚硝化的非甾族化合物抗炎化合物，以及包含至少一种亚硝化和/或亚硝基化的非甾体抗炎化合物的新组合物，以及任选的至少一种捐赠，转移或释放一氧化氮的化合物，提高内源性水平 的内皮衍生的松弛因子，刺激一氧化氮的内源性合成或是一氧化氮合酶的底物。 本发明还提供了治疗，预防和/或减轻炎症，疼痛和发烧的方法; 减少或逆转使用非甾体抗炎药引起的胃肠道，肾脏和其他毒性; 治疗和/或预防胃肠道疾病; 治疗炎性疾病状态和障碍; 以及治疗和/或预防眼科疾病或病症。

    NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE
    62.
    发明公开
    NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE 审中-公开
    NITRO和α-肾上腺素能受体，SETS方法和用途镀锌亚硝拮抗剂

    公开(公告)号：EP1109542A1

    公开(公告)日：2001-06-27

    申请号：EP99944040.7

    申请日：1999-09-01

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S. ,  SCHROEDER, Joseph, D. ,  SAENZ DE TEJADA, Inigo ,  GASTON, Ricky, D. ,  SHELEKHIN, Tatiana, E. ,  WANG, Tiansheng

    IPC分类号： A61K31/13 ,  A61K31/195 ,  A61K31/415

    CPC分类号： C07D459/00 ,  A61K45/06 ,  C07C381/00 ,  C07D211/62 ,  C07D233/24 ,  C07D239/95 ,  C07D401/04 ,  C07D405/12 ,  Y10S514/929 ,  Y10S514/968

    摘要： The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

    METHODS USING HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE
    66.
    发明公开
    METHODS USING HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE 审中-公开
    使用方法和HYDRALAZINVERBINDUNGEN消心痛或硝酸异山梨醇酯的

    公开(公告)号：EP1984010A2

    公开(公告)日：2008-10-29

    申请号：EP07750648.3

    申请日：2007-02-12

    申请人： Nitromed, Inc.

    发明人： LOBERG, Michael, D.

    IPC分类号： A61K38/00

    CPC分类号： A61K45/06 ,  A61K31/15 ,  A61K31/34 ,  A61K31/50 ,  A61K31/502 ,  A61K31/5025 ,  A61K2300/00

    摘要： The invention provides methods for (a) treating decompensated heart failure; (b) treating compensated heart failure; (c) treating renovascular diseases and (d) treating end-stage renal diseases in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound or a pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of an angiotensin converting enzyme inhibitor, a β-adrenergic antagonist, an angiotensin II antagonist, an aldosterone antagonist, a cardiac glycoside (digitalis) and a diuretic compound or a combination of two or more thereof. The hydralazine compound may be hydralazine hydrochloride.

    THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM
    67.
    发明公开
    THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM 审中-公开
    遗传风险评估心力衰竭：遗传变异对GLY389ARG-多态性BETA 1肾上腺素能受体的影响

    公开(公告)号：EP1945030A2

    公开(公告)日：2008-07-23

    申请号：EP06816322.9

    申请日：2006-10-04

    申请人： Nitromed, Inc. ,  University of Pittsburgh of the Commonwealth System of Higher Education

    发明人： WORCEL, Manuel ,  SABOLINSKI, Michael L. ,  TAM, Sang, William ,  McNAMARA, Dennis M.

    IPC分类号： A01N43/58

    CPC分类号： C12Q1/6883 ,  A61K31/34 ,  A61K31/502 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

    摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B- type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, compiising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

    ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION
    68.
    发明授权
    ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION 有权
    刺激内源性NO的合成低氧条件下

    公开(公告)号：EP1082112B1

    公开(公告)日：2008-04-09

    申请号：EP99925993.0

    申请日：1999-06-01

    申请人： Nitromed, Inc.

    发明人： SAENZ DE TEJADA, Inigo

    IPC分类号： A61K31/155

    CPC分类号： A61K45/06 ,  A61K31/155 ,  A61K31/198

    摘要： The present invention provides methods of promoting synthesis of nitric oxide or endothelium-derived relaxing factor (EDRF) in hypoxic mammalian tissues by administering at least one N-hydroxyguanidine compound that is a substrate of nitric oxide synthase, and, optionally, one or more vasoactive agents. The present invention also provides methods of promoting relaxation of vascular and non-vascular smooth muscle and treating sexual dysfunctions in patients by administering at least one N-hydroxyguanidine compound that is a substrate for nitric oxide synthase, and, optionally, one or more vasoactive agents. The present invention also provides methods for treating clinical conditions resulting from hypoxic conditions, such as pulmonary disease, cardiovascular disorders, circulatory hypoxia, specific organ hypoxia, localized hypoxia, edema, central nervous system disorders, memory loss, or arterial disease. The present invention also provides methods for treating clinical conditions associated with deficient nitric oxide pathways by administering at least one N-hydroxyguanidine compound and, optionally, one or more vasoactive agents. The present invention also provides pharmaceutical compositions comprising at least one N-hydroxyguanidine compound and, optionally, one or more vasoactive agents.